MIF anticorps

N° du produit ABIN7881520

L’anticorps anti-MIF Monoclonal Souris est utilisé pour la détection de MIF dans des échantillons de Humain. Il a été validé pour WB et IHC (p).

Aperçu rapide pour MIF anticorps (ABIN7881520)

Antigène: MIF (Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor) (MIF))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp MIF est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: MIF-6280

Détail du produit anti-MIF anticorps

Fonction: MIF Antibody / GLIF / Glycosylation inhibiting factor (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: A recombinant fragment of human protein was used as the immunogen for the MIF antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal dilution of the MIF antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: -20 °C

Stockage commentaire: Aliquot the MIF antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur MIF

Antigène: MIF (Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor) (MIF))

Autre désignation: MIF

Sujet: Macrophage migration inhibitory factor, known as MIF or glycosylation inhibiting factor, is a secreted, homotrimeric, pro-inflammatory cytokine that modulates macrophage and T cell function and is an important regulator of host response to infection. MIF is expressed at sites of inflammation, which suggests that it plays a role in regulating macrophage function in host defense. MIF is produced by the pituitary gland and is found in monocytes, macrophages, differentiating immunological cells in the eye lens and brain, and fibroblasts. Elevated levels of MIF protein are detected in the plasma of patients with severe sepsis or septic shock, a condition where MIF influences endotoxic shock by enhancing the production of other inflammatory cytokines including tumor necrosis factor Alpha (TNF-Alpha), interleukin-1 (IL-1) and interferon-Gamma (IFN-Gamma). MIF promotes the systemic inflammatory response by counter-regulating glucocorticoid-mediated inhibition of immune-cell activation and proinflammatory cytokine production. MIF may mediate tissue destruction through the induction of proteinases.

UniProt: P14174

Pathways: Regulation of Systemic Arterial Blood Pressure by Hormones, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Regulation of Carbohydrate Metabolic Process, Feeding Behaviour, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling